Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients wit...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Baird, John H., Epstein, David J., Tamaresis, John S., Ehlinger, Zachary, Spiegel, Jay Y., Craig, Juliana, Claire, Gursharan K., Frank, Matthew J., Muffly, Lori, Shiraz, Parveen, Meyer, Everett, Arai, Sally, Brown, Janice (Wes), Johnston, Laura, Lowsky, Robert, Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Latchford, Theresa, Sahaf, Bita, Mackall, Crystal L., Miklos, David B., Sidana, Surbhi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2021
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7805341/
https://ncbi.nlm.nih.gov/pubmed/33570626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002732
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia